Tim Eisen - Concepedia

Author

Tim Eisen

Royal Marsden Hospital ORCID

Also Known As

De Ruysscher, Eisen, Tim, M Gore, T EISEN, T Eisen, T G Eisen, T G G Eisen, T. Eisen, T. G. Eisen, T.G. Eisen

253

Publications

18.4K

Citations

H-Index

Concepts

All Affiliations

Royal Marsden Hospital University of Cambridge Cambridge University Hospitals NHS Foundation Trust Addenbrooke's Hospital Royal Marsden NHS Foundation Trust

About

Tim Eisen is an author at Royal Marsden Hospital specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	40	2.6K
2	Health Sciences	5	5	547
3	Public Health	3	3	170
4	Cell Biology	3	3	148
5	Biostatistics	1	1	26

Tim Eisen

Publications

15.3K

Citations

H-Index

Page 1

	Year	Citations
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma Bernard Escudier, Tim Eisen, Walter M. Stadler, New England Journal of Medicine	2007	4.8K
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial Bernard Escudier, Tim Eisen, Walter M. Stadler, Journal of Clinical Oncology	2009	1.1K
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Mark J. Ratain, Tim Eisen, Walter M. Stadler, Journal of Clinical Oncology	2006	1K
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis Tim Eisen, T. Ahmad, Keith T. Flaherty, British Journal of Cancer	2006	633
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Paul J. Ross, S. Ashley, A. Norton, British Journal of Cancer	2004	470
Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study Bernard Escudier, Camillo Porta, Petri Bono, Journal of Clinical Oncology	2014	438
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial Andrew J. Armstrong, Susan Halabi, Tim Eisen, The Lancet Oncology UrologyGenitourinary CancerMedicineRandomised Phase 2Cancer Treatment	2016	420
Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC) Bernard Escudier, Cezary Szczylik, Tim Eisen, Journal of Clinical Oncology UrologyVegfr Inhibitor SorafenibGenitourinary CancerMedicinePhase Iii Trial	2005	350
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer Tim Eisen, Chris Boshoff, Ian Mak, British Journal of Cancer	2000	341
The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer John K. Field, Stephen W. Duffy, David Baldwin, Health Technology Assessment	2016	274

Page 1